Literature DB >> 33271079

Prevalence, risk factors, and management of dementia and mild cognitive impairment in adults aged 60 years or older in China: a cross-sectional study.

Longfei Jia1, Yifeng Du2, Lan Chu3, Zhanjun Zhang4, Fangyu Li1, Diyang Lyu1, Yan Li1, Yan Li1, Min Zhu1, Haishan Jiao1, Yang Song1, Yuqing Shi1, Heng Zhang1, Min Gong1, Cuibai Wei1, Yi Tang1, Boyan Fang5, Dongmei Guo1, Fen Wang1, Aihong Zhou1, Changbiao Chu1, Xiumei Zuo1, Yueyi Yu1, Quan Yuan1, Wei Wang1, Fang Li6, Shengliang Shi7, Heyun Yang8, Chunkui Zhou9, Zhengluan Liao10, Yan Lv11, Yang Li12, Minchen Kan13, Huiying Zhao14, Shan Wang15, Shanshan Yang16, Hao Li17, Zhongling Liu18, Qi Wang1, Wei Qin1, Jianping Jia19.   

Abstract

BACKGROUND: China has a large population of older people, but has not yet undertaken a comprehensive study on the prevalence, risk factors, and management of both dementia and mild cognitive impairment (MCI).
METHODS: For this national cross-sectional study, 46 011 adults aged 60 years or older were recruited between March 10, 2015, and Dec 26, 2018, using a multistage, stratified, cluster-sampling method, which considered geographical region, degree of urbanisation, economic development status, and sex and age distribution. 96 sites were randomly selected in 12 provinces and municipalities representative of all socioeconomic and geographical regions in China. Participants were interviewed to obtain data on sociodemographic characteristics, lifestyle, medical history, current medications, and family history, and then completed a neuropsychological testing battery administered by a psychological evaluator. The prevalence of dementia (Alzheimer's disease, vascular dementia, and other dementias) and MCI were calculated and the risk factors for different groups were examined using multivariable-adjusted analyses.
FINDINGS: Overall age-adjusted and sex-adjusted prevalence was estimated to be 6·0% (95% CI 5·8-6·3) for dementia, 3·9% (3·8-4·1) for Alzheimer's disease, 1·6% (1·5-1·7) for vascular dementia, and 0·5% (0·5-0·6) for other dementias. We estimated that 15·07 million (95% CI 14·53-15·62) people aged 60 years or older in China have dementia: 9·83 million (9·39-10·29) with Alzheimer's disease, 3·92 million (3·64-4·22) with vascular dementia, and 1·32 million (1·16-1·50) with other dementias. Overall MCI prevalence was estimated to be 15·5% (15·2-15·9), representing 38·77 million (37·95-39·62) people in China. Dementia and MCI shared similar risk factors including old age (dementia: odds ratios ranging from 2·69 [95% CI 2·43-2·98] to 6·60 [5·24-8·32]; MCI: from 1·89 [1·77-2·00] to 4·70 [3·77-5·87]); female sex (dementia: 1·43 [1·31-1·56]; MCI: 1·51 [1·43-1·59]); parental history of dementia (dementia: 7·20 [5·68-9·12]; MCI: 1·91 [1·48-2·46]); rural residence (dementia: 1·16 [1·06-1·27]; MCI: 1·45 [1·38-1·54]); fewer years of education (dementia: from 1·17 [1·06-1·29] to 1·55 [1·38-1·73]; MCI: from 1·48 [1·39-1·58] to 3·48 [3·25-3·73]); being widowed, divorced, or living alone (dementia: from 2·59 [2·30-2·90] to 2·66 [2·29-3·10]; MCI: from 1·58 [1·44-1·73] to 1·74 [1·56-1·95]); smoking (dementia: 1·85 [1·67-2·04]; MCI: 1·27 [1·19-1·36]), hypertension (dementia: 1·86 [1·70-2·03]; MCI: 1·62 [1·54-1·71] for MCI), hyperlipidaemia (dementia: 1·87 [1·71-2·05]; MCI: 1·29 [1·21-1·37]), diabetes (dementia: 2·14 [1·96-2·34]; MCI: 1·44 [1·35-1·53]), heart disease (dementia: 1·98 [1·73-2·26]; MCI: 1·17 [1·06-1·30]), and cerebrovascular disease (dementia: 5·44 [4·95-5·97]; MCI: 1·49 [1·36-1·62]). Nine of these risk factors are modifiable.
INTERPRETATION: Dementia and MCI are highly prevalent in China and share similar risk factors. A prevention strategy should be developed to target the identified risk factors in the MCI population to thwart or slow down disease progression. It is also crucial to optimise the management of dementia and MCI as an important part of China's public health system. FUNDING: Key Project of the National Natural Science Foundation of China, National Key Scientific Instrument and Equipment Development Project, Mission Program of Beijing Municipal Administration of Hospitals, Beijing Scholars Program, Beijing Brain Initiative from Beijing Municipal Science & Technology Commission, Project for Outstanding Doctor with Combined Ability of Western and Chinese Medicine, and Beijing Municipal Commission of Health and Family Planning.
Copyright © 2020 The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY-NC-ND 4.0 license. Published by Elsevier Ltd.. All rights reserved.

Entities:  

Year:  2020        PMID: 33271079     DOI: 10.1016/S2468-2667(20)30185-7

Source DB:  PubMed          Journal:  Lancet Public Health


  120 in total

1.  Prognostic value of color Doppler ultrasound, D-dimer, and Lp-PLA2 levels in carotid atherosclerotic stenosis.

Authors:  Yu Kong; Ying Kong; Yunyi Dai; Jianping Zhang
Journal:  Am J Transl Res       Date:  2021-12-15       Impact factor: 4.060

Review 2.  Spousal caregiving, widowhood, and cognition: A systematic review and a biopsychosocial framework for understanding the relationship between interpersonal losses and dementia risk in older adulthood.

Authors:  E Lydia Wu-Chung; Stephanie L Leal; Bryan T Denny; Samantha L Cheng; Christopher P Fagundes
Journal:  Neurosci Biobehav Rev       Date:  2021-12-29       Impact factor: 8.989

3.  Population-attributable fractions of risk factors for all-cause dementia in China rural and urban areas: a cross-sectional study.

Authors:  Fei-Fei Hu; Gui-Rong Cheng; Dan Liu; Qian Liu; Xu-Guang Gan; Lin Li; Xiao-Dan Wang; Bo Zhang; Li-Na An; Cong Chen; Ming-Jun Zou; Lang Xu; Yang-Ming Ou; Yu-Shan Chen; Jin-Quan Li; Zhen Wei; Yue-Yi Wang; Qiong Wu; Xing-Xing Chen; Xi-Fei Yang; Qing-Ming Wu; Lei Feng; Jing-Jing Zhang; Heng Xu; Ya-Fu Yu; Meng-Liu Yang; Jin Qian; Peng-Fei Lian; Li-Yan Fu; Ting-Ting Duan; Yuan Tian; Xi Cheng; Xin-Wen Li; Pin-Ting Yan; Guowei Huang; Hongxin Dong; Yong Ji; Yan Zeng
Journal:  J Neurol       Date:  2021-11-28       Impact factor: 4.849

Review 4.  Factors affecting the efficacy of repetitive transcranial magnetic stimulation for patients with Alzheimer's disease.

Authors:  Jintao Wang; Lei Huang; Lili Wei; Wei Chen
Journal:  Zhejiang Da Xue Xue Bao Yi Xue Ban       Date:  2021-06-25

5.  Association between body mass index, its change and cognitive impairment among Chinese older adults: a community-based, 9-year prospective cohort study.

Authors:  Shanshan Wu; Xiaozhen Lv; Jie Shen; Hui Chen; Yuan Ma; Xurui Jin; Jiaxi Yang; Yaying Cao; Geng Zong; Huali Wang; Changzheng Yuan
Journal:  Eur J Epidemiol       Date:  2021-08-09       Impact factor: 8.082

6.  A Rare Variation in the 3' Untranslated Region of the Presenilin 2 Gene Is Linked to Alzheimer's Disease.

Authors:  Yana Pang; Tingting Li; Qi Wang; Wei Qin; Ying Li; Yiping Wei; Longfei Jia
Journal:  Mol Neurobiol       Date:  2021-05-19       Impact factor: 5.590

7.  Associations Between Mild Cognitive Impairment and Whole Blood Zinc and Selenium in the Elderly Cohort.

Authors:  Jinhui Yu; Yu He; Xuemin Yu; Ling Gu; Qunan Wang; Sufang Wang; Fangbiao Tao; Jie Sheng
Journal:  Biol Trace Elem Res       Date:  2022-02-03       Impact factor: 3.738

8.  The Relationship Between Mild Cognitive Impairment and Anti-Inflammatory/Pro-Inflammatory Nutrients in the Elderly in Northern China: A Bayesian Kernel Machine Regression Approach.

Authors:  Ruiqiang Li; Wenqiang Zhan; Xin Huang; Limin Zhang; Zechen Zhang; Meiqi Zhou; Zhihong Wang; Yuxia Ma
Journal:  J Inflamm Res       Date:  2022-01-14

Review 9.  Prevalence of mild cognitive impairment in patients with hypertension: a systematic review and meta-analysis.

Authors:  Jiawei Qin; Zexiang He; Lijian Wu; Wanting Wang; Qiuxiang Lin; Yiheng Lin; Liling Zheng
Journal:  Hypertens Res       Date:  2021-07-20       Impact factor: 3.872

10.  Mobile Phone Use and Cognitive Impairment among Elderly Chinese: A National Cross-Sectional Survey Study.

Authors:  Shige Qi; Yuying Sun; Peng Yin; Han Zhang; Zhihui Wang
Journal:  Int J Environ Res Public Health       Date:  2021-05-26       Impact factor: 3.390

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.